Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Change in Inventory: 2009-2025

Historic Change in Inventory for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Sep 2025 value amounting to $17.5 million.

  • UNITED THERAPEUTICS's Change in Inventory rose 54.87% to $17.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.7 million, marking a year-over-year increase of 12.77%. This contributed to the annual value of $46.9 million for FY2024, which is 244.85% up from last year.
  • According to the latest figures from Q3 2025, UNITED THERAPEUTICS's Change in Inventory is $17.5 million, which was up 136.49% from $7.4 million recorded in Q2 2025.
  • In the past 5 years, UNITED THERAPEUTICS's Change in Inventory registered a high of $17.5 million during Q3 2025, and its lowest value of -$5.7 million during Q1 2022.
  • For the 3-year period, UNITED THERAPEUTICS's Change in Inventory averaged around $8.8 million, with its median value being $9.3 million (2024).
  • Data for UNITED THERAPEUTICS's Change in Inventory shows a peak YoY increase of 13,800.00% (in 2022) and a maximum YoY decrease of 359.09% (in 2022) over the last 5 years.
  • Over the past 5 years, UNITED THERAPEUTICS's Change in Inventory (Quarterly) stood at $100,000 in 2021, then surged by 13,800.00% to $13.9 million in 2022, then tumbled by 49.64% to $7.0 million in 2023, then spiked by 65.71% to $11.6 million in 2024, then spiked by 54.87% to $17.5 million in 2025.
  • Its Change in Inventory stands at $17.5 million for Q3 2025, versus $7.4 million for Q2 2025 and $11.2 million for Q1 2025.